^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ADI-001

i
Other names: ADI-001, ADI001, ADI 001
Company:
Adicet Bio
Drug class:
γδ TCR modulator, CD20-targeted CAR-T immunotherapy
Related drugs:
7ms
A Phase 1 Study of ADI-001 in Lupus Nephritis (clinicaltrials.gov)
P1, N=40, Not yet recruiting, Adicet Bio, Inc
New P1 trial
|
cyclophosphamide • fludarabine IV • ADI-001
8ms
GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov)
P1, N=78, Recruiting, Adicet Bio, Inc | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • ADI-001
1year
Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (ASH 2023)
ADI-001 Cmax and D28 persistent exposure were comparable to, or exceeded, those demonstrated by alternative allogeneic CAR T therapies and approved autologous CD19 CAR T therapies. Favorable clinical responses were also associated with higher mean and median peak of ADI-001 cells.
Clinical • PK/PD data
|
IL15 (Interleukin 15)
|
ADI-001
3years
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2 (ASH 2021)
The secondary objectives for Parts 1, 2 and 3 include PK, immunogenicity, and antitumor activity of ADI-001 monotherapy or in combination with IL-2. This study is currently enrolling in 4 U.S. sites (NCT04735471).
Clinical • P1 data • IO biomarker
|
CD19 (CD19 Molecule) • IL2 (Interleukin 2)
|
CD20 negative
|
ADI-001